/
CBUS
$1.43+$0.07 (+5.15%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$103.8M
76M shares
52-week range
$1.09 – $4.19
11% from low
Sector
AGRICULTURAL CHEMICALS
Exchange
NASDAQ
CS
Borrow rate
4.87%
Moderate
Price (6 mo)
Loading chart…
Change$-24.62
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $236.0K | $7.3M | $23.9M | $26.0M | $157.0K | $1.8M | $4.3M | $3.6M |
| Cost of revenue | $1.1M | $9.3M | $35.1M | $28.6M | $1.5M | $395.0K | $0 | $5.9M |
| Gross profit | −$845.0K | −$2.0M | −$11.3M | −$2.6M | −$1.4M | $1.4M | $4.3M | −$2.3M |
| Gross margin | -358.1% | -27.2% | -47.3% | -9.9% | -877.1% | 78.3% | 100.0% | -62.8% |
| R&D | $9.8M | $12.2M | $11.1M | $11.3M | $11.6M | $42.4M | $50.4M | $44.2M |
| Operating income | −$28.1M | −$39.7M | −$43.8M | −$29.3M | −$22.4M | −$318.9M | −$258.4M | −$67.5M |
| EBITDA | −$25.6M | −$36.5M | −$41.5M | −$25.4M | −$15.2M | −$314.6M | −$241.6M | −$90.8M |
| Net income | −$27.9M | −$39.6M | −$44.8M | −$29.2M | −$16.9M | −$267.6M | −$251.4M | −$127.1M |
| Net margin | -11820.8% | -542.9% | -188.0% | -112.4% | -10758.6% | -14729.1% | -5898.4% | -3492.3% |
| EPS (diluted) | -45.46 | -60.37 | -66.16 | -0.05 | -0.03 | -25.95 | -10.83 | -2.78 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-1.22 | $-1.35–$-1.08 | 2 |
| 2027 | $14M | $-0.91 | $-0.93–$-0.89 | 2 |
| 2028 | $42M | $-0.84 | $-1.21–$-0.48 | 2 |
| 2029 | $159M | $0.28 | $0.22–$0.34 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Cibus, Inc. Class A Common Stock
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
www.cibus.com- Employees
- 118
- IPO / List date
- Jul 20, 2017
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CBUS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 98,900 | $195.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-04-25 | 1-for-10reverse |
| 2008-05-06 | 4-for-1 |
Recent trades on TradeandTell
No one on the platform has traded CBUS yet.
